Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Mild Cognitive Impairment: early-phase trial registry
100 of 206 indexed Mild Cognitive Impairment trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #45 of 28,707 conditions by registered trial count.
206 US clinical trials · 100 currently recruiting · #45 of 28,707 conditions by registered trial count
Mild Cognitive Impairment: 206 US clinical trials tracked, 100 recruiting.
Mild Cognitive Impairment is the subject of 206 registered US clinical trials on ClinicalTrials.gov, 100 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 52 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 9 of these trials.
Enrollment posture brief
Registry condition mild-cognitive-impairment
OPEN 100 | RECR 49% | LATE 8 | EARLY 52 | RANK #45 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Chronic Graft Versus Host Disease (48% recruiting · 31 trials)
Mild Cognitive Impairment lists 100 open slots (49% of 206 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Mild Cognitive Impairment on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Mild Cognitive Impairment is recruiting above its size-band peers.
100 of 206 indexed trials (48.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Mild Cognitive Impairment trials is spread across many organizations.
Massachusetts General Hospital accounts for 9 of 206 trials (4.4%). 114 distinct sponsors appear on at least one study for this condition label.
-
Typical Mild Cognitive Impairment enrolment sits around 81 participants.
Median target enrolment is 81 among the 206 trials that report a genuine target (sentinel values excluded). 114 of those (55.3%) plan for fewer than 100 participants.
-
Mild Cognitive Impairment research is mostly interventional.
168 interventional and 38 observational studies make up this index (81.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
206 total, page 2 of 5
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
University of Rochester
NCT04522791
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
Yaakov Stern
NCT03372317
bpMedManage: Digital Technology to Support Adherence to Hypertension Medications
University of Arizona
NCT06307574
Working Memory and Physical Exercise Training in Patients With Mild Cognitive Impairment
University of Maryland, Baltimore
NCT05948930
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
National Institute of Mental Health (NIMH)
NCT07169630
Treating Hyperexcitability in AD With Levetiracetam
Beth Israel Deaconess Medical Center
NCT03875638
Multimodal Investigation of Neural Plasticity
University of Michigan
NCT06453980
Targeted Transcranial Magnetic Stimulation to Improve Hippocampal-dependent Declarative Memory Abilities
University of Nebraska
NCT03574207
tDCS for Post-Stroke Cognitive Impairment
University of Oklahoma
NCT06516588
Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History
University of Texas Southwestern Medical Center
NCT05446584
MCI Speech in Noise
Dartmouth-Hitchcock Medical Center
NCT06102486
Individual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease
Massachusetts General Hospital
NCT05904132
Promoting Independence With Compensatory Cognitive Rehabilitation
University of Delaware
NCT04820335
Online Interplay Between Deciding and Acting With Mild Cognitive Impairment
University of Delaware
NCT06493422
Improving Physical Activity With Cognitive Impairment
Creighton University
NCT05370118
Home Sleep Therapy for Older Adults With MCI
Brain Electrophysiology Laboratory Company
NCT05771844
Transcranial Magnetic Stimulation for MCI
Medical University of South Carolina
NCT05992831
The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
UConn Health
NCT06027554
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
University of California, San Diego
NCT06548191
Music Therapy for Patients With Alzheimer's Disease
Johns Hopkins University
NCT05151562
rTMS to Improve Cognition in Parkinson's
VA Office of Research and Development
NCT03836950
Senicapoc in Alzheimer's Disease
University of California, Davis
NCT04804241
Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)
Johns Hopkins University
NCT04601038
Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia
Mclean Hospital
NCT04430517
CogT pSOPT Intervention Study
Stanford University
NCT06005038
OTC Hearing Aid and MCI
Northwestern University
NCT06112860
A rTMS and Virtual Reality Based Cognitive Rehabilitation Program for MCI
Central Arkansas Veterans Healthcare System
NCT06024473
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
Oregon Health and Science University
NCT05591027
A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
Indiana University
NCT06403345
Rapamycin - Effects on Alzheimer's and Cognitive Health
The University of Texas Health Science Center at San Antonio
NCT04629495
Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside
Mclean Hospital
NCT05245903
Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
Butler Hospital
NCT04500847
Impact of Intensive Computerized Cognitive Training
Brigham and Women's Hospital
NCT06130735
Olfactory Training in Mild Cognitive Impairment
Jeffrey Motter
NCT06825403
Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease
Massachusetts General Hospital
NCT06538311
Assessing Cognitive Decline at Home
Stanford University
NCT06704971
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
Johns Hopkins University
NCT04123314
Feasibility and Adherence to a Technology-assisted Home-based Strength Training Program in Adults With Type 2 Diabetes Mellitus and Mild Cognitive Impairment
The University of Texas Medical Branch, Galveston
NCT07416799
The Use of Rhythmic Light Therapy in Mild Cognitive Impairment
Icahn School of Medicine at Mount Sinai
NCT07318038
Evaluate the Effect of Atorvastatin on Cerebrovascular Reactivity in Mild Cognitive Impairment (MCI)
Johns Hopkins University
NCT04765137
Voice Technology-Based Self-Management Intervention
Emory University
NCT06982261
Effects of Transcranial Ultrasound Stimulation (TUS) on Neurological and Cognitive Outcomes in Neurodegenerative Diseases
Sanmai Technologies PBC dba Sanmai
NCT07207122
OCT Angiography and NRAI in Dementia
Oregon Health and Science University
NCT03761381
Engage for Late-Life Depression and Comorbid Executive Dysfunction
University of Nevada, Las Vegas
NCT05356611
Innate Immunity Stimulation Via TLR9 in Early AD
NYU Langone Health
NCT05606341
Feasibility of Implementing Time-restricted Eating in Women With Mild Cognitive Impairment
Julie Pendergast
NCT05858008
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
Mark Tuszynski
NCT05040217
Combined STN and NBM Deep Brain Stimulation for Mild Cognitive Impairment in Parkinson's Disease
Helen M. Bronte-Stewart
NCT05968703
Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease
Emory University
NCT06484244
Race-Based Stress and Cognitive Training for MCI
Rosalind Franklin University of Medicine and Science
NCT06330844
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 24 |
| Phase 2 | 28 |
| Phase 3 | 3 |
| Phase 4 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Mild Cognitive Impairment records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Mild Cognitive Impairment trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Mild Cognitive Impairment page
206 registered trials, 100 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 100 Mild Cognitive Impairment trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Massachusetts General Hospital sponsors the most Mild Cognitive Impairment trials on record, review their full trial history before evaluating a specific study. See Massachusetts General Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Mild Cognitive Impairment condition card totals 206 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.